Trial Profile
A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary) ; Linagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 26 Oct 2015 Planned initiation date changed from 1 Apr 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
- 26 Oct 2015 Planned number of patients changed from 400 to 160 as reported by ClinicalTrials.gov record.
- 05 May 2015 New trial record